Plain-English translation of NCT07368270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of cell therapy for adults with a type of lymphoma called diffuse large B-cell lymphoma that has come back or stopped responding to standard treatments. The treatment involves taking your own immune cells, engineering them in a lab to recognize and attack cancer cells, and then infusing them back into your body. Researchers want to find the right dose and learn how safe and effective this medication is.
Many patients with aggressive lymphoma don't respond well to standard chemotherapy or their cancer returns. This trial exists because researchers believe that engineering your own immune cells to be "smarter" and more powerful against lymphoma cells might offer a new hope for patients who have limited options.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first receive chemotherapy drugs (fludarabine and cyclophosphamide) to prepare your body for the new cells. Your immune cells will then be collected, sent to a laboratory to be engineered, and after a few weeks, infused back into your body. You'll be monitored closely during and after the infusion with multiple visits, blood tests, and scans to watch for side effects and to see how well the treatment is working. The trial will test three different dose levels to find the safest and most effective amount.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Enrollment target
~30 participants
Started
January 2026
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiao Ma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.